Lexaria Bioscience Corp’s disruptive new technology DehydraTECH™ is available to be licensed.
DehydraTECH™ can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
DehydraTECH™ is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system. Lexaria has, or is conducting, in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of cannabinoids through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased absorption rate, and reported improvements in taste and smell of edible products.
Regulations in jurisdictions such as California, Pennsylvania, Nevada, Canada and others all place limitations on the quantity of cannabinoids that are allowable in each edible serving size. With tightly controlled limits, edible manufacturers trying to gain a competitive edge cannot do so by increasing the quantities of cannabinoids, and must therefore increase the quality of the edible experience through taste, rapidity of onset, and overall absorption. Lexaria is not aware of any other technology solution that addresses all three of these needs in a single, inexpensive step.
Contact Lexaria’s President to speak about your licensing needs at [email protected].
Lexaria makes its technology available through either semi-exclusive or exclusive access to a defined geographic region(s) for a set period of time and limited to defined product categories. The number of licenses available both by location and by product sector are STRICTLY LIMITED. Lexaria charges its licensees fees for territory rights plus a royalty or usage fee on DehydraTECH™-powered product sales. Fees for territory rights vary depending on the jurisdiction, exclusivity and term provisions desired by our licensees.
Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH™ technology for the license prospect`s needs. Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH™ technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.
We will license our technology in any of the more than 40 countries around the world where the DehydraTECH™ is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio will help to provide a competitive edge and protection against inferior methodology.
Licensees should also always remember that DehydraTECH™ costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics. Customers will be loyal to the improved performance of DehydraTECH™ based products.
We will license the DehydraTECH™ process to existing or new companies looking to improve delivery characteristics in any of these sectors:
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Increases bio-absorption by 5 – 10x, to equate or exceed that of other routes of administration like inhalational delivery.
Avoids first-pass liver metabolism
Initial testing indirectly evidences DehydraTECH™ may deliver molecules through the lymphatic system instead of being subject to immediate liver exposure, potentially mitigating unwanted side effects.